Recently，Bio-Techne announced that it has agreed to acquire Advanced Cell Diagnostics for $250 million in cash, plus an additional consideration of $75 million if certain milestones are achieved. 

"We are very pleased to have ACD as part of Bio-Techne," said President and CEO Charles Kummeth in a statement. "ACD marks Bio-Techne's entry into the genomics field and market."

ACD was founded in 2006 by current CEO Yuling Luo and Steve Chen, and has more than 100 employees. ACD develops and commercializes consumables for use in genomic analysis, and has a current product line of more than 9,000 probe reagents and reagent kits for manual and automated use sold worldwide. The company also markets an RNA in-situ hybridization technology called RNAscope, which enables researchers to visualize expression of many genes in individual cells while retaining information on tissue morphology.

"ACD's innovative and versatile technology has the potential to change pathology practices. RNA-ISH is a transformative technology facilitating and improving the monitoring of gene expression patterns at the single-cell level, while retaining the morphological context of the tissue being analyzed," Kummeth said. "ACD's technology serves both research and diagnostic markets, expanding Bio-Techne's presence in the clinical lab setting. With broader adoption of the technology in the diagnostic arena, it has the potential to revolutionize the choice of reagents in diagnostic practices, such as oncology, infectious diseases, and others."

In March, Bio-Techne announced it had acquired single-cell western blotting firm Zephyrus Biosciences for an undisclosed amount. The company said it would integrate Zephyrus into its protein platforms division.